Passage Bio, Inc. (NASDAQ:PASG) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET

Company Participants

Stuart Henderson - VP, Corporate Development and Investor Relations

William Chou - Chief Executive Officer

Mark Forman - Chief Medical Officer

Simona King - Chief Financial Officer

Conference Call Participants

Brendan Smith - Cowen

Neena Bitritto-Garg - Citi

Laura Chico - Wedbush

Danielle Brill - Raymond James

Yun Zhong - BTIG

Operator

Good morning and welcome to the Passage Bio Third Quarter 2022 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that this call is being recorded at the company's request.

Now I'd like to turn the call over to Stuart Henderson, Vice President of Corporate Development and Investor Relations. Stuart, please proceed.

Stuart Henderson

Thank you, operator. This morning we issued a press release that outlines the topics we plan to discuss today. This release is available on the Passage Bio website under the Press Releases and Statements section of Investors and News.

On today's call our recently appointed Chief Executive Officer, Will Chou, will review our third quarter 2022 and recent business highlights; Mark Forman, our Chief Medical Officer, will review our clinical programs; and Simona King, our Chief Financial Officer, will review our third quarter 2022 financial results.

Before we begin, please note that today's call may include a number of forward-looking statements including, but not limited to, comments on our expectations about timing and execution of anticipated milestones, including the initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners' ability to execute key initiatives; the ability of our lead product candidates to treat their respective target CNS disorder; manufacturing plans and strategies; our expectations with respect to cash runway and trends with respect to financial performance and cash flows; the company's ability to fund research and development programs; impact of the COVID-19 pandemic on the company's operations; and its ability to manage costs along with uses of cash and other matters.

These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements.

Please refer to the company's filings with the SEC for information concerning risk factors that could cause its actual results to differ materially from expectations, including any forward-looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call.